Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO)

Chronic Limb Ischemia Clinical Trial

— TANGO  

Official title:

TANGO: Temsirolimus Adventitial Delivery to Improve ANGiographic Outcomes Below the Knee

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02908035
• Other study ID #: CIP0214
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: March 3, 2017
• Est. completion date: September 2021

Study information

• Verified date: June 2020
• Source: Mercator MedSystems, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, multi-center, randomized, dose escalation study to document the effects of adventitial delivery of temsirolimus (Torisel) after revascularization of lesions below the knee in symptomatic patients with critical limb ischemia (CLI).

Description:

This is a prospective, multi-center, randomized, dose escalation study to document the effects of adventitial delivery of temsirolimus (Torisel) after revascularization of lesions below the knee in symptomatic patients with critical limb ischemia (CLI). Up to 60 patients (20 low-dose, 20 high-dose and 20 control) at up to 15 sites in the United States. This study will assess the safety and effectiveness of Bullfrog Micro-Infusion Device adventitial deposition of temsirolimus in reducing intimal hyperplasia, inflammatory markers and composite safety endpoints in patients with clinical evidence of chronic critical limb ischemia after revascularization of one or more angiographically significant lesion(s) in below-knee popliteal or tibial vessels.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 100
• Est. completion date: September 2021
• Est. primary completion date: September 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

Screening Criteria:

• Age =18 years and <90 years

• Patient has been informed of the nature of the study, agrees to participate and has signed an IRB approved consent form

• Female patients of childbearing potential have a negative pregnancy test =7 days before the procedure and are willing to use a highly effective method of birth control (See Section 12.2) one month preceding and 12 months following study treatment

• Patient has documented chronic Critical Limb Ischemia (CLI) in the target limb from the distal segment (P3) of the popliteal artery to the ankle joint prior to the study procedure with Rutherford Category 3, 4 or 5

• Life expectancy >1 year in the Investigator's opinion

Angiographic Criteria:

• Target vessel(s) diameter =2 mm and =8 mm

• Single or multiple atherosclerotic lesion(s) =70% in at least one below-knee popliteal or tibial target vessel including the tibioperoneal trunk that totals up to no greater than 30 cm in length (with no greater than 5 cm length of contiguous intervening normal artery), with possible extension into the popliteal artery distal to the center of the knee joint space (the P3 segment)

• Successful revascularization of the TL with less than 30% residual stenosis, run-off down to the foot and direct in-line flow to any foot wound, if a wound is present at baseline

Exclusion Criteria:

• Screening Criteria

• Patient is already enrolled in another clinical study of systemic drug therapy or another device study that has not completed its primary endpoint

• Patient unwilling or unlikely to comply with visit schedule

• Patients who are incapable of providing consent and/or incapable of understanding the nature, significance and implications of the clinical trial

• Patient is already receiving or planned to receive systemic immunotherapy, chemotherapy, or steroids (however, inhaled steroids for asthma treatment or topical steroid uses are allowed)

• Patient has a bilirubin level of >1.5xULN

• Recent (<30 days prior to study procedure) myocardial infarction

• Cerebrovascular accident <60 days prior to the study procedure

• Planned major (above the ankle) target limb amputation

• Active foot infection; however, osteomyelitis in the toes or mild cellulitis around the perimeter of gangrene or small ulcers (<25mm) are not exclusions, but osteomyelitis of the metatarsal or more proximal region would be exclusionary

• Inability to receive temsirolimus or iodinated contrast medium due to labeled contra-indications or known sensitivity reactions Estimated glomerular filtration rate (eGFR, calculated from serum creatinine using an isotope dilution mass spectrometry (IDMS)-traceable equation) less than 30 mL/min, except for patients with end stage renal disease on chronic hemodialysis

• Stage 3 (per SVS WIfI classification) or worse heel ulcers or heel ulcers that are determined to be primarily neuropathic in nature or non-ischemic in origin

Angiographic/Procedural Criteria

• Hemodynamically significant inflow lesion (=50% DS) or occlusion in the ipsilateral iliac, SFA, or popliteal arteries (P1 and P2) in which there is failure to successfully treat and obtain a <30% residual stenosis post-revascularization, with bailout stenting as needed (in-flow lesions should be treated prior to treating the target lesion)

• Target lesion length is >30 cm as measured from proximal normal vessel to distal normal vessel

• Total length of lesions treated during the case (including target lesion, inflow lesions, and other non-target lesions) >30 cm

• Use of alternative therapy, e.g. radiation therapy, drug-eluting stents (DES) or drug-eluting balloon/drug-coated balloons (DEB/DCB) as part of the target lesion treatment or during the previous 2 months within the target lesion

• Previously implanted stent in the TL(s)

• Aneurysm in the target vessel

• Acute thrombus in the target limb

• Failure to cross the TL with a guide wire; however, subintimal wire crossing is allowed

• Heavy eccentric or concentric calcification at target lesion, which in the judgment of the investigator would prevent penetration of the Micro-Infusion Device needle through the vessel wall

Related Conditions & MeSH terms

• Chronic Limb Ischemia
• Ischemia

Intervention

Drug:
• Temsirolimus
After completion of revascularization therapy and any decision to place stents, patients will be qualified for final enrollment in the study and will be treated with the investigational drug or saline. Investigators will be blinded to assignment.
• Saline
After completion of revascularization therapy and any decision to place stents, patients will be qualified for final enrollment in the study and will be treated with the investigational drug or saline. Investigators will be blinded to assignment.

Locations

Country	Name	City	State
United States	University Hospital	Cleveland	Ohio
United States	Denver Veterans Administration Hospital	Denver	Colorado
United States	Baylor College of Medicine	Houston	Texas
United States	Arkansas Heart Hospital	Little Rock	Arkansas
United States	Advocate Christ Medical Center	Oak Lawn	Illinois
United States	St. Joseph Hospital of Orange Heart and Vascular Center	Orange	California
United States	Einstein Medical Center	Philadelphia	Pennsylvania
United States	Sanford Research	Sioux Falls	South Dakota

Sponsors (1)

Lead Sponsor	Collaborator
Mercator MedSystems, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Freedom from MALE-POD	Freedome from MALE-POD at 30 days.	Up to 30 days post-procedure
Primary	Transverse-view vessel area loss percentage (TVAL%) of the target lesion	Transverse-view vessel area loss percentage (TVAL%) of the target lesion at 6 months by quantitative vascular angiography (QVA) or prior to any TLR of the target lesion before 6 months.	Within 6 months post-procedure
Secondary	Freedom from a composite of all-cause death, MALE and unplanned minor amputation in target limb	Freedom from a composite of all-cause death within 30 days from the index procedure, major adverse limb event (MALE) of the target limb, unplanned minor amputation in the target limb, and clinically driven target lesion revascularization (CD-TLR) within 6 months.	Up to 30 days post-procedure
Secondary	Freedom from a composite of death, unplanned minor amputation, clinically driven TLR, and major adverse limb events (MALE)	Freedom from a composite of death, unplanned minor amputation, clinically driven TLR, and major adverse limb events (MALE) up to 12 months from the procedure for all subjects.	Up to 12 months post-procedure
Secondary	Freedom from Serious Adverse Events (SAEs)	Freedom from serious adverse events (SAE) to 12 months from the procedure for all subjects.	Up to 12 months post-procedure
Secondary	Event-free survival	Event-free survival to 12 months from the procedure for all subjects.	Up to 12 months post-procedure
Secondary	Improvement in % diameter stenosis and maximum late lumen loss (LLL) of the target lesion	6-month improvement % diameter stenosis (%DS) of the target lesion (TL) and the maximum late lumen loss for the lesion (LLL) will be assessed by Quantitative Vascular Angiography.	Up to 6 months post-procedure
Secondary	Improvement in luminal volume by intravascular ultrasound (IVUS)	6-month improvement in luminal volume as measured by intravascular ultrasound (IVUS) within the TL (subgroup analysis).	Up to 6 months post-procedure
Secondary	Composite of major amputation, target vessel occlusion or CD-TLR	A composite at 12 months of freedom from major amputation, target vessel occlusion, or CD-TLR.	Up to 12 months post-procedure